RIGEL PHARMACEUTICALS INC's ticker is RIGL and the CUSIP is 766559603. A total of 140 filers reported holding RIGEL PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.10 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,620,000 | +83620.9% | 1,500,000 | 0.0% | 1.72% | -8.9% |
| Q2 2023 | $1,935 | -2.3% | 1,500,000 | 0.0% | 1.89% | -19.7% |
| Q1 2023 | $1,980 | -12.0% | 1,500,000 | 0.0% | 2.35% | -12.5% |
| Q4 2022 | $2,250 | -99.9% | 1,500,000 | +15.4% | 2.69% | +57.0% |
| Q3 2022 | $1,534,000 | +4.4% | 1,300,000 | 0.0% | 1.71% | +9.5% |
| Q2 2022 | $1,469,000 | -36.6% | 1,300,000 | +67.7% | 1.56% | -19.6% |
| Q1 2022 | $2,317,000 | +12.8% | 775,000 | 0.0% | 1.94% | +25.3% |
| Q4 2021 | $2,054,000 | -24.6% | 775,000 | +3.3% | 1.55% | -23.6% |
| Q3 2021 | $2,723,000 | -16.3% | 750,000 | 0.0% | 2.03% | -13.6% |
| Q2 2021 | $3,255,000 | +90.4% | 750,000 | +50.0% | 2.35% | +85.1% |
| Q1 2021 | $1,710,000 | +22.1% | 500,000 | +25.0% | 1.27% | -2.1% |
| Q4 2020 | $1,400,000 | – | 400,000 | – | 1.30% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CM Management, LLC | 1,500,000 | $1,620,000 | 1.72% |
| Soleus Capital Management, L.P. | 14,803,015 | $15,987,256 | 1.48% |
| ARMISTICE CAPITAL, LLC | 17,136,000 | $18,506,880 | 0.28% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,228,126 | $1,326,376 | 0.24% |
| GSA CAPITAL PARTNERS LLP | 971,441 | $1,049 | 0.09% |
| NJ State Employees Deferred Compensation Plan | 200,000 | $216,000 | 0.03% |
| Providence Wealth Advisors, LLC | 27,500 | $29,013 | 0.03% |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 1,151,765 | $1,243,906 | 0.03% |
| XTX Topco Ltd | 164,238 | $177,377 | 0.03% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 3,369,076 | $3,638,602 | 0.02% |